Hjem › Brystkræft › Utah
Brystkræft kliniske forsøg i Utah
42 studier for Brystkræft søger deltagere på steder i Utah.
Byer i Utah
Officiel studietekst (engelsk)
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Intermountain Medical Center ( Site 0074), Murray
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06966700Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Salt Lake City
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT07085767A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Utah Cancer Specialists, Salt Lake City
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07174336A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- Huntsman Cancer Institute, Salt Lake City
RekruttererFase 2
Alder 18 og opefter · Kvinder · Opdateret 22. sep. 2026 · NCT07287098A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- START Center for Cancer Research, West Valley City
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 17. sep. 2026 · NCT07109726A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Utah Cancer Specialists, Salt Lake City
- Huntsman Cancer Institute, University of Utah, Salt Lake City
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 15. sep. 2026 · NCT06492616A Phase 1/1b Study of IAM1363 in HER2 Cancers
- START Mountain Region, West Valley City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 9. sep. 2026 · NCT06253871A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- University of Utah Huntsman Cancer Institute, Salt Lake City
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 8. sep. 2026 · NCT07100106A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- START Mountain Region, West Valley City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 4. sep. 2026 · NCT06400472Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
- START Mountain Region, West Valley City
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 4. sep. 2026 · NCT07287917Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Huntsman Cancer Institute, University of Utah, Salt Lake City
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 3. sep. 2026 · NCT06982521A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Huntsman Cancer Hospital at the University of Utah, Salt Lake City
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 3. sep. 2026 · NCT06790693Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Farmington Health Center, Farmington
- University of Utah Sugarhouse Health Center, Salt Lake City
- Huntsman Cancer Institute/University of Utah, Salt Lake City
- og 1 flere
RekruttererFase 3
Alder 18 til 60 · Kvinder · Opdateret 2. sep. 2026 · NCT05879926A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- South Texas Accelerated Research Therapeutics (START) Mountain Region, West Valley City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 28. aug. 2026 · NCT07029399A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
- START Mountain Region, LLC, West Valley City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 26. aug. 2026 · NCT07383506A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Intermountain/LDS Hospital Ph 1 Research Program, Salt Lake City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 21. aug. 2026 · NCT06774963Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
- Huntsman Cancer Institute at University of Utah, Salt Lake City
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 20. aug. 2026 · NCT07203378Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
- Huntsman Cancer Institute/University of Utah, Salt Lake City
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 17. aug. 2026 · NCT06500481A Study of MGC026 in Participants With Advanced Solid Tumors
- START Mountain Region, West Valley City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 11. aug. 2026 · NCT06242470Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- University of Utah - Huntsman Cancer Institute, Salt Lake City
RekruttererFase 3
Alder 18 til 100 · Alle køn · Opdateret 6. aug. 2026 · NCT05232916Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- START Mountain Region, West Valley City
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 4. aug. 2026 · NCT05579366A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
- START Mountain Region, West Valley City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. jul. 2026 · NCT07318805First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- START Mountain Region, West Valley City
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 7. jul. 2026 · NCT05768139A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Huntsman Cancer Institute, Salt Lake City
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 29. jun. 2026 · NCT05377996A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Huntsman Cancer Institute, Salt Lake City
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 6. maj 2026 · NCT07062965I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Huntsman Cancer Institute, University of Utah, Salt Lake City
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 6. maj 2026 · NCT01042379Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
- George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 30. apr. 2026 · NCT05297734De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- American Fork Hospital / Huntsman Intermountain Cancer Center, American Fork
- Sandra L Maxwell Cancer Center, Cedar City
- Logan Regional Hospital, Logan
- og 7 flere
RekruttererFase 3
Alder 50 til 70 · Alle køn · Opdateret 23. apr. 2026 · NCT04852887A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- START Center for Cancer Care - Mountain Region, Salt Lake City
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 27. mar. 2026 · NCT06395519Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System
- Huntsman Cancer Institute at University of Utah, Salt Lake City
RekruttererTidlig fase 1
Alder 18 og opefter · Kvinder · Opdateret 17. mar. 2026 · NCT05291507Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
- START, Mountain Region, West Valley City
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 17. feb. 2026 · NCT07145255Improving Care for Rural Patients With Solid Tumors
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
Rekrutterer
Alder 18 til 99 · Alle køn · Opdateret 5. feb. 2026 · NCT049169905 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer
- Huntsman Cancer Institute/University of Utah, Salt Lake City
RekruttererFase 2
Alder 18 og opefter · Kvinder · Opdateret 9. dec. 2025 · NCT06961955SAVE Trial: SAfe Opioid Use Video Education
- University of Utah Huntsman Cancer Institute, Salt Lake City
Rekrutterer
Alder 18 og opefter · Kvinder · Opdateret 26. nov. 2025 · NCT07044583Enhancing Mammography Programs for Outreach, Wellness, Education, and Resources (EMPOWER) in Underserved Populations Study
- Huntsman Cancer Institute/ University of Utah, Salt Lake City
RekruttererFrivillige med god helbredstilstand velkomne
Alder 18 og opefter · Kvinder · Opdateret 21. nov. 2025 · NCT07029490SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Salt Lake City
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 28. okt. 2025 · NCT03452774Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
- START - Mountain Region, West Valley City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 10. okt. 2025 · NCT06784193Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies
- Huntsman Cancer Institute at University of Utah, Salt Lake City
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 3. okt. 2025 · NCT07166042First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- University of Utah- Huntsman Cancer Center, Salt Lake City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2025 · NCT05216432MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
- Ogden Regional Cancer Center, Ogden
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 20. aug. 2025 · NCT03053193Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.